Abstract
Major progress has been made in the treatment of chronic hepatitis C virus (HCV) infection over the 18 years since Hoofnagle et al. initially documented response of non-A non-B hepatitis to interferon alfa. Current optimal therapy with pegylated interferon alfa (PEG-IFN) and ribavirin results in sustained virologic response rates of just over 50%. With an estimated 2.7 million Americans with active HCV infection, we can anticipate a large number of potential treatment failures with the current standard of care. At this time, no therapy is approved by the US Food and Drug Administration for treatment failures of PEG-IFN and ribavirin. Maintenance interferon therapy with the goal of prevention of disease progression rather than viral eradication appears to offer an option for HCV treatment failures with advanced disease. Alternative medical strategies to reduce hepatic fibrosis are also under investigation. With the relatively static number of available organs for transplantation, prevention of disease progression and decompensation is essential for an impact to be made upon the predicted rates of HCV morbidity and mortality in the next 10 to 20 years.
Similar content being viewed by others
References and Recommended Reading
Alter MJ. Epidemiology of hepatitis C. Hepatology 1997, 26(Suppl 1):62S-65S.
Davis GL, Albright JE, Cook SF, Rosenberg DM: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331–338. Outlines the scale of the HCV epidemic and projects future impact on health-care resource.
Poynard T, Bedossa P, Chevallier M, et al.: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995, 332:1457–1462.
McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485–1492.
Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.
Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.
Fried MW SM, Reddy RK, et al.: Pegylated interferon alfa-2b in combination with ribavirin: efficacy and safety results from a phase III, randomised, actively controlled, multi center trial [abstract]. Gastroenterology 2001, 120(Suppl 1):288.
Lau JY, Davis GL, Prescott LE, et al.: Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 1996, 124:868–876.
Davis GL, Esteban-Mur R, Rustgi V, et al.: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1493–1499.
Poynard T, Marcellin P, Lee SS, et al.: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426–1432.
Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265–2271.
Bruno S, Silini E, Crosignani A, et al.: Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997, 25:754–758.
Arif A, Levine RA, Sanderson SO, et al.: Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003, 48:1425–1430.
Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303–1313. This study documents the potential of PEG-IFN to reverse fibrosis in those with chronic HCV infection.
Sobesky R, Mathurin P, Charlotte F, et al.: Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999, 116:378–386.
Shiffman ML, Hofmann CM, Contos MJ, et al.: A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999, 117:1164–1172.
Nishiguchi S, Kuroki T, Nakatani S, et al.: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995, 346:1051–1055.
Okanoue T, Itoh Y, Minami M, et al.: Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999, 30:653–659. This study outlines the efficacy of interferon in reducing the rate of hepatocellular carcinoma among a cohort of patients with HCV.
Valla DC, Chevallier M, Marcellin P, et al.: Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999, 29:1870–1875.
Imai Y, Kawata S, Tamura S, et al.: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998, 129:94–99.
International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998, 351:1535–1539.
Pawlotsky JM, Dahari H, Neumann AU, et al.: Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004, 126:703–714.
Bodenheimer HC Jr, Lindsay KL, Davis GL, et al.: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997, 26:473–477.
Dusheiko G, Main J, Thomas H, et al.: Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996, 25:591–598.
Hoofnagle JH, Ghany MG, Kleiner DE, et al.: Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003, 38:66–74.
Dienstag JL, Goldin RD, Heathcote EJ, et al.: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105–117.
Yoshiji H, Kuriyama S, Fukui H: Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma: possible role of vascular endothelial growth factor. Tumour Biol 2002, 23:348–356.
Dooley S, Hamzavi J, Breitkopf K, et al.: Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003, 125:178–191.
Canbay A, Feldstein A, Baskin-Bey E, et al.: The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004, 308:1191–1196.
Orr JG, Leel V, Cameron GA, et al.: Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells. Hepatology 2004, 40:232–242.
Yano M, Hayashi H, Yoshioka K, et al.: A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol 2004, 39:570–574.
Carlo C, Daniela P, Giancarlo C: Iron depletion and response to interferon in chronic hepatitis C. Hepatogastroenterology 2003, 50:1467–1471.
Yano M, Hayashi H, Wakusawa S, et al.: Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002, 97:133–137.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kelleher, T.B., Afdhal, N.H. Maintenance therapy for chronic hepatitis C. Curr Gastroenterol Rep 7, 50–53 (2005). https://doi.org/10.1007/s11894-005-0066-1
Issue Date:
DOI: https://doi.org/10.1007/s11894-005-0066-1